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Abstract 
As part of our effort to deliver masked phosphates inside living cells we have discovered that certain phosphate triester derivatives of the inactive 
nucleoside analogue, dideoxy uridine (ddU) are inhibitors of HIV replication at PM levels. Moreover, we note that certain phosphoramidate 
derivatives retain their activity in thymidine kinase-deficient cells, which indicates that they do indeed act by intracellular elease of the free nucleotide, 
and that they successfully by-pass the nucleoside kinase. The increased structural freedom in drug design which this allows may have implications 
for dealing with the emergence of resistance and may stimulate the discovery of improved therapeutic agents. 
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1. Introduction 
Although nucleoside analogues, such as 3’-azidothy- 
midine (AZT, 1, Fig. 1) continue to dominate anti-HIV 
drug therapy they have a number of major limitations, 
such as their inherent toxicity, a dependence on kinase- 
mediated activation to generate the bio-active 
(tri)phosphate forms, and the emergence of resistance 
[l-2]. 
We [3-61 and others [7-91 have pursued a masked 
phosphate approach in an attempt to improve on the 
therapeutic potential of the parent nucleoside analogues. 
In this approach, inactive phosphate derivatives of the 
nucleoside analogue are designed to penetrate the cell 
membrane and liberate the bio-active nucleotides intra- 
cellularly. Masking of the phosphate group is necessary 
on account of the extremely poor membrane penetration 
by the polar (charged) free nucleotide. One mechanism 
by which masked phosphates may lead to enhanced 
selectivity of action arises from what we have termed 
‘kinase bypass’ [3]. Thus, the complete dependence of 
administered (anti-HIV) nucleoside analogues on host 
nucleoside kinase-mediated activation places constraints 
upon the structures of nucleoside analogues which might 
be active. Nucleoside analogues which fall outside these 
strict constraints will be inactive, even if their 5’-tri- 
phosphates (the bio-active form) are potent and selective 
inhibitors of a viral target, such as reverse transcriptase 
(RT). Several such cases are known. Dideoxythymidine, 
and 3’-O-methylthymidine are examples of nucleoside 
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analogues which are inactive against HIV, whilst their 
triphosphates are exceptionally potent inhibitors of HIV 
RT [lo]; the inactivity of the nucleoside being attributed 
to poor phosphorylation by host kinases. If the masked 
phosphate strategy were able to deliver nucleotides in- 
tracellularly, the nucleoside kinase would be by-passed 
and the structural constraints uch host enzymes impose 
would be obviated. In this way, wider structural varia- 
tion of the nucleoside analogue would be permitted, and 
more specific (less toxic) inhibitors of viral function may 
arise. We have recently reported on the success of this 
‘kinase by-pass’ strategy with several highly modified 
3’-substituted nucleosides [1 l-l 21. 
We now report the success of this approach with the 
simple nucleoside analogue dideoxy uridine (ddU, 2). 
This is essentially inactive against HIV, but judicious 
phosphorylation leads to the introduction of a signifi- 
cant, selective antiviral effect. Moreover, this effect is 
retained in thymidine kinase-deficient cells, indicating a 
successful by-pass of this enzyme, and strongly support- 
ing the suggested intracellular delivery of free nucleotides 
by this strategy. Whilst other researchers have recently 
reported the failure of the by-pass approach with 
phosphoramidates derived from ddu [13], we herein 
clearly demonstrate the success of this strategy with our 
previously reported aryloxy phosphoramidates [6] 
2. Materials and methods 
2.1. Chemistry 
General synthetic procedures were similar to those we have described 
[S]. All nucleotides were pure by high-field multi-nuclear NMR and 
reverse phase High Performance Liquid Chromatography (HPLC: 
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ACS system, 50 + 250 mm x 4.6 mm, Spherisorb 0DS2 5 p column, 
gradient elution using 5% acetonitrile in-water (A), and 5% water in 
acetonitrile (B). with 20% B for O-10 min. then a linear gradient to 80% \ II 
B at 30 min, with a flow rate of 1 ml/min). 
2.1.1. 2’,3’-dideoxy uridine (ddlJ, 2). 
(a) 5’-Trityl uridine. Trityl chloride (4.1 g, 14.7 mmol) was added to 
a solution of uridine (3 g, 12.3 mmol) in pyridine (50 ml) and the 
reaction mixture heated at 50°C for 24 h. The solvent was removed 
under high vacuum and the residue purified by chromatography on 
silica using 5% methanol in chloroform as eluant. Pooling and evapora- 
tion of appropriate fractions, followed by recrystallisation from ethanol 
gave the product as a white solid (5.32 g, 89%). G,(d,-DMSO) 3.3(28, 
dd, H5’, J = 10.8, 4.5 Hz), 4.0(1H, m, H3’), 4.15(28, m, H2’, H4’), 
5.2(IH, d, OH, J = 4.8 Hz), 5.35(1H, d, H5,J = 8.1 Hz), 5.6(1H, d, 
OH,J = 3.7 Hz), 5.8(1H, d, HI’, 3 = 3.1 Hz), 7.2-7.5(15H, m, Ar), 
7.8(lH, d, H6, J = 8.1 Hz), 11.2(lH, s,NH). &(d,- DMSO) 63.24(CS), 
69.56(C3’), 73.44(C2’), 82.36(C4’), 86,45(Cl’), 88.97(CPh,), 101.47(C5); 
127.18, 127.00,128.32(Ar), 140.62(C6), 143,43(Ar), 150,52(C4), 
163.07(C2). 
(h) 5’-Trityl-2’.3’-thiocarbonyl uridine. A solution of 5’-trityl uridine 
(1 g, 2.05 mmol) and thiocarbonyldiimidazole (400 mg, 2.24 mmol) in 
THF (20 ml) was stirred at ambient temperature for 17 h. After evap- 
oration of the solvent under reduced pressure the residue was purified 
by chromatography on silica using 5% methanol in chloroform as 
eluant. Pooling and evaporation of appropriate fractions gave the prod- 
uct as a white solid (990 mg, 91%). 6, (CDCI,) 3.5(2H, m, HS), 4.5(1 H, 
m, H4’), 5.5(lH, m, H2’); 5.65.9(2H,m, H3’, H5), 7.2-7.6(16H,m, Ar, 
H6), 9.5(lH, s, NH). 
(c) 2’,3’-Didehydro-2’,3’-dideoxy uridine (d4l.f). A solution of thio- 
carbonate (850 mg, 1.61 mmol) in triethylphosphite (10 ml) was heated 
at 150°C for 30 min. Excess triethylphosphite was evaporated under 
high vacuum and the residue purified by chromatography on silica 
using 5% methanol in chloroform as eluant. Pooling and evaporation 
of appropriate fractions gave the product and triethylphosphite 
(ratio = 60/40 by NMR). This mixture was dissolved in acetic acid and 
left for 17 h with stirring at ambient temperature. The solid obtained 
after evaporation of the solvent was purified by chromatography on 
silica using 8% methanol in chloroform as eluant. Pooling and evapora- 
tion of appropriate fractions gave the product (240 mg, 71%). 
6, (CDCI,. CD,OD) 3.7(28, dd, H5’. J = 12.3, 3.0 Hz’), 
4:85(lH, m, H4’);5.6(lH, d, H5, J = 8.1 Hz), 5.8(1H, m, H2’), 6.3(IH, 
m. H3’). 6.9(1H. m. HI’). 7.7(1H. d.H6. J = 8.1 Hz). 6,(CDCI,. 
CD,ODj 62.&l(&), ‘87.4i(C4’),‘89.86(Cl’j, 101.95(C5): 12?81(C2’j; 
134.71(C3’), 141.29(C6), 15l.Ol(C4), 164.25(C2). 
(d) 2’,3’-dideoxy uridine (2, ddll). D4U (240 mg, 1.14 mmol) was 
dissolved in methanol (10 ml) and ethanol (10 ml) and 10% palladium 
on charcoal (200 mg) was added. This mixture was shaken under a 
hydrogen atmosphere for 4 h.The catalyst was removed by filtration 
through celite and the residue purified by chromatography on silica 
using 8% methanol in chloroform as eluant. Pooling and evaporation 
of appropriate fractions gave the product as a white solid (200 mg, 
83%). 6, tCDCI,,CD,OD) l.9-2.1(3H, m, H2’,H3’), 2.4(1H, m, H2’), 
3,8(2H,‘hd, H5’, J =-12.2; 2.7 Hz); 4.15(1H, m, H4’), 5.7(lH, d, H5, 
J = 8.1 Hz).6.0(1H.Hl’.dd.J =6.6.3.3Hz)7.9(lH.d.H6.J =8.l Hz): 
FAB MS ‘m/e ‘213,0886(MH’, 72% C H N-0 requires 213.0875), 9 I? 2 4 
149(32), 137(93), 129(40), 113(68), lOl(1OO). 
2.1.2. 2:3’-Dideoxy uridine 5’-bis[2,2,2-trichloroethyl] phosphate 
(3a). DdU (2) (0.08 g, 0.38 mmol) and N-methyl imidazole (0.155 g, 
1.89 mmol) were mixed in THF (10 ml ) and bis(2,2,2-trichloroethyl) 
phosphorochloridate (0.186 g, 0.49 mmol) was added slowly at ambient 
temperature. After I h the solvent was evaporated and the residue 
dissolved in CHCI, (30 ml) washed with HCI (1 M; 10 ml), sodium 
bicarbonate solution (15 ml) and water (15 ml). The organic phase was 
dried (MgSO,) and evaporated under reduced pressure. The crude 
product was purified by chromatography on silica eluting with 4% 
methanol in chloroform. Pooling and evaporation of appropriate frac- 
tions under reduced pressure gave the product (0.20 g, 95%). 
6,, (CDCI,) 2.1(3H, m, H2’, H3’), 2.45(18, m, H2’), 4.4(28, m, 
HS), 4.55(18, m, H4’), 4.7(4H, m, CHZOP), 5.75(1H, d, H5, J = 8 Hz), 
6.l(lH, m, HI’), 7.6(1H, d, H6, J = 8 Hz), 9.4(lH, s, NH); FAB MS 
m/e 552,8792(MH’, lo%, C,,H,,N20,PCI, requires 552.8826); HPLC 
RT = 32.6 min. 
2.1.3. 2’.3’-Dideoxy uridine 5’-(ethyl methoxyalaninyl)phosphate 
(3b). DdU (2) (0.05 g, 0.23 mmol) and N-methyl imidazole (0.09 g, 
1.18 mmol) were mixed in THF (IO ml) and ethyl methoxyalaninyl 
phosphorochloridate (0.11 g, 0.47 mmol) was added slowly at ambient 
temperature. After 4h the solvent was evaporated and the crude prod- 
uct purified entirely as described for (3a) above, except that a second 
chromatographic column was necessary, using an eluant of 15% meth- 
anol in diethyl ether, in order to obtain pure (3b) (0.051 g, 54%). 
&(CDCI,) 1.3(6H, m, Ala-Me, POCC), 2.0(3H, m, H2’, H3’). 
2.4(lH,m, H2’), 3.70,3.71(3H, s, OMe), 3.84.25(7H,m, Ala-CH, Ala- 
NH, H4’, H5’, POC), 5.7(lH, d, H5, J = 8 Hz), 6.05(lH, m, Hl’), 
7.68,7.73(lH,d,H6,J=8Hz),9.5(lH,bs,NH);FABMSm/e406.1392 
(MH’, IO%, CSH,,N,O,P requires 406.1379) 294( IOO), 94(7); HPLC 
RT = 29.9,30.3 min. 
2.1.4. 2’,3’-dideoxy uridine 5’-(phenyl methoxyalaninyl)pho.sphate 
(3~). This was prepared by a procedure which was entirely analogues 
to (3a) above, except that the reaction was stirred for 17 h, and 4% 
methanol in chloroform was used as chromatographic eluant. Thus, 
from 92 mg of ddU was isolated 178 mg (90%) of (3~). 6, (CDCI,) 
1.32,1.33(3H, d, Ala-Me, J = 7 Hz), 1.8-2.1(3H, m, H2’,H3’), 2.3(IH, 
m, H2’), 3.66,3.67(3H, s, OMe), 4.0(lH, m, Ala-CH), 4.34.4(4H, m, 
H4’, HS’, Ala-NH), 5.60,5.65(1H, d, H5, J = 9 Hz), 6.0(lH. m, Hl’), 
7.25(5H. m. Ph). 7.60.7.61(18. d. H6, J = 8 Hz). lO.O(lH, bs. NH): 
FAB MS m/e 454.1397 (M-H’, 13% C&H,,N,O,P requires 454.1379) 
342(35), 307(14), ZOO(l5); 154(100),136(79); HPLC RT = 34.4, 34.6 
min. 
2.2. Virology 
2.2. I. Antiviral assays. The anti-HIV-1 activities and toxicities of 
compounds were assessed in two cell lines 1141. C8166 (a normal T-cell 
transformed by co-cultivation with leukaemialymphocytes harbouring 
HTLV-I) were infected with the III-B strain of HIV-l. Secondly. JM, 
a semi-mature T-cell line derived from a patient with lymphoblastic 
leukaemia, were infected with HIV-I strains GB8 or BIB. JM cells are 
relatively resistant to the antiviral effects of AZT and a number of its 
derivatives. 
Cells were grown in RPM1 1640 with 10% calf serum. 4 x IO4 cells 
per microtiter plate well were mixed with 5-fold dilutions of compound 
prior to addition of IO CCID,,, units of virus and incubated for 557 
days. Formation of syncytia was examined from 2 days post-infection. 
Culture fluid was collected at 557 davs and an120 antigen production 
measured by ELISA. Cell viability ofinfectezcells andcytotoxicity to 
uninfected cell controls were assessed by the MTT-Formazan method 
1151. 
2.2.2. gpl20 antigen assay. A microtiter antigen capture ELISA 
was developed [16] using a lectin (GNA) from Galanthus nivalis (Vector 
Labs., Peterborough, UK) and anti-HIV antibodies in human serum. 
The plates were coated with lectin (0.5pg), and after blocking with 10% 
calf serum, dilutions of virus supernatants in 0.25% Empigen solution 
(Albright and Wilson Ltd., Whitehaven, UK) were added to the wells 
and incubated at 4°C for 12-16 h. Bound antigen was detected using 
human anti-HIV-I antibodies, and anti-human IgG antibodies coupled 
to horseradish peroxidase. 
3. Results and discussion 
Dideoxy uridine (ddU, 2) was prepared via three inde- 
pendent routes, all involving a final hydrogenation of the 
didehydro dideoxy compound d4U. Thus, 5’-silylation of 
uridine, followed by thiocarbonate formation, elimina- 
tion with triethyl phosphite, and deprotection with fluo- 
ride, gave 2’,3’-dideoxy 2’,3’-didehydro uridine (d4U) 
[17] in an overall yield of 50%. Alternatively, a 5’-trityl 
protecting group could be used in this synthesis to give 
d4U, again via the 2’,3’-thiocarbonate, in an overall yield 
of 58%. Alternatively, by the procedures of Horwitz [18] 
2’-deoxyuridine could be converted to its 3’,5’-dimesyl- 
ate, which gave the 3’,5’-oxetane, and which could be 
converted to d4U on treatment with strong base. The 
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Fig. 1. The structures of potential anti-HIV nucleoside and nucleotide 
analogues. 
overall yield by this route was 29%. Thus, in terms of 
yield the best route to d4U was via the 5’-trityl protected 
2’,3’- thiocarbonate. 
The didehydro compound d4U generated by either of 
these routes was hydrogenated to give ddU (2) in 83% 
yield, and the structure and purity of this compound was 
confirmed by ‘H, 13C NMR, mass spectrometry and 
HPLC. 
The nucleoside analogue was then subjected to 5’- 
phosphorylation with a range of phosphates. A labile 
phosphate blocking group is clearly a pre-requisite for 
the masked phosphate approach, in order to facilitate 
(intracellular) release of the free nucleotides. Thus, sim- 
ple dialkyl phosphate derivatives of AZT are extremely 
resistant to phosphate hydrolysis, and they display no 
antiviral effect [3]. On the other hand bis(trihaloethy1) 
phosphate derivatives of zidovudine and of 2’,3’-dide- 
oxycytidine (ddC) show significant lability towards hy- 
drolysis [ 191, and are potent inhibitors of viral prolifera- 
tion [5]. We have also noted that one of these phosphate 
masking groups, the bis(2,2,2-trichloroethyl) phosphate 
moiety is successful in the kinase by-pass activation of 
certain inactive 3’-modified nucleosides [l l-121. We 
therefore chose this phosphate as the first blocking group 
for ddU. 
Thus, ddU was allowed to react with bis(2,2,2-trichlo- 
roethyl) phosphorochloridate in tetrahydrofuran con- 
taining N-methyl imidazole at room temperature to give 
(3a) in good yield. This was fully characterised by heter- 
onuclear NMR, FAB mass spectrometry, and HPLC, all 
data being consistent with its structure and purity. We 
have also noted that certain phosphoramidate deriva- 
tives of AZT are potent and selective inhibitors of HIV 
[4]. Thus, ethyl methoxyalaninyl phosphorochloridate 
was prepared by methods we have reported [4] and was 
allowed to react with ddU to give the target compound 
(3b) in moderate yield. This compound was recently re- 
ported by another group, following our earlier phosphor- 
amidate strategy [13]. However, we have found that 
aryloxy phosphoramidates are especially potent phos- 
phate blocking groups for AZT, and appear to release 
the free nucleotides within cells, on the basis of data in 
thymidine kinase-deficient cells [6,20]. Thus, phenyl 
methoxyalaninyl phosphorochloridate was similarly pre- 
pared [20] and was allowed to react with ddU to give (3~) 
in good yield. Full carbon-13 and (where appropriate) 
phosphorus-3 1 NMR data for the nucleoside (2) and the 
phosphates (3a-c) are given in Table 1. 
The parent nucleoside (2) and the corresponding 
masked phosphates (3a-c) were tested for their ability to 
inhibit the replication of HIV-l in C8166 cells, and in 
thymidine kinase-deficient [JM] cells, data being pre- 
sented in Table 2. As expected, the parent nucleoside (2) 
is active only at the highest concentrations tested, and is 
essentially inactive in JM cells. The bis[trichloroethyl] 
phosphate (3a) is approximately 5-10 times more active 
in each assay. On the other hand, the simple phospho- 
ramidate (3b) is devoid of antiviral activity in this assay, 
as has been recently noted by other researchers in a 
different assay [ 131. However, the aryloxy phosphorami- 
date (3~) is a potent agent, being approximately 50-times 
more active than the parent nucleoside analogue. This 
confirms the importance of data derived from assays in 
kinase deficient cells for the interpretation of the activi- 
ties of blocked nucleotides. As we have noted [20] only 
Table 1 
Carbon-13 and phosphorus-31 NMR data for compounds (2) and 
(3ac) 
2 3a 3b 3c 
Base C2 
c4 
c5 
C6 
Sugar Cl’ 
C2’ 
C3’ 
c4 
C5’ 
P-OR POC 
POCC 
P-OAr Cl” - 
C2” 
C3” 
C4” 
P-NHR PNC 
c=o 
OMe 
164.3 
150.5 
101.4 
140.8 
89.3 
24.6 
32.5 
81.8 
62.6 
_ 
CHMe - - 
SP _ 
163.4 
150.6 
102.6 
139.7 
86.6 
25.5 
32.2 
78.66 
69.6 
77.3” 
94.7’O 
-3.6 
163.9 163.7 
150.7 150.4 
102.1 101.9, 102.0 
140.0 139.7 
86.5, 86.3 85.9, 86.2 
25.3, 25.4 25.0, 25.2 
32.5, 32.6 32.0, 32.1 
79.46 78.86 
66.5, 66.8 66.9, 67.0 
66.0 _ 
16.2, 16.3 - 
_ 150.5 
119.8, 1 19.95 
_ 129.6, 129.7 
_ 125.0 
50.0, 50.1 50.0, 50.2 
174.4, 174.3” 173.8, 174.0’ 
52.6 52.4 
21.1, 21.05 20.6, 20.7 
7.2(d) 3.2 
“Multiplet. All spectra were recorded in CDCI,, except for (2) which 
were recorded in CDCI, plus CD,OD. Data are presented as 6 in ppm. 
All spectra were recorded using proton decoupling. In the case of 
carbon data phosphorus coupling constants in Hz are superscripted. 
Many carbon peaks for (3b-c) display diastereomeric splitting arising 
from mixed stereochemistry at the phosphate centre. 
14 C. McGuigan et al. IFEBS Letters 351 (1994) II-14 
Table 2 
Anti-HIV1 activity of nucleoside and nucleotide analogues 
Compound C8166 JM 
ED,, CCS” ED,,, CC,” 
2 200 > 1,000 1,000 > 1,000 
3a 40 500 80 400 
3b > 1,000 > 1,000 400 400 
3c 4 400 20 500 
The antiviral activity and cytotoxicity of test compounds in two differ- 
ent cell lines. ED,, represents the concentration of compound (in ,uM) 
that decreases viral antigen production in infected cells to 50% of 
control. CC,, represents the concentration of compound (in ,uM) which 
causes 50% cytotoxicity to uninfected cells. 
such data will allow a clear understanding of the likely 
mechanism of action of blocked nucleotides, and dis- 
criminate between the release of nucleosides and nucleo- 
tides. 
In conclusion, we report the antiviral activity of cer- 
tain masked phosphate derivatives of the inactive nucle- 
oside ddU. We note that aryloxy phosphoramidates are 
particularly efficacious, and attribute the introduction of 
activity to kinase by-pass. Finally we stress the impor- 
tance of data in kinase-deficient cells for the clear inter- 
pretation of results on blocked phosphates. 
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